Redmile Group’s Blueprint Medicines BPMC Stock Holding History

Redmile Group’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-94,405	Closed	-$10.2M	–	64
2024 Q2	$10.2M	Sell	94,405 -18,655	-17%	-$1.87M	0.62%	39
2024 Q1	$10.7M	Buy	+113,060	New	+$9.7M	0.39%	58
2017 Q3	–	Sell	-367,537	Closed	-$18.6M	–	68
2017 Q2	$18.6M	Sell	367,537 -32,463	-8%	-$1.38M	1.13%	33
2017 Q1	$16M	Buy	+400,000	New	+$14.3M	1.04%	38
2016 Q4	–	Sell	-27,539	Closed	-$818K	–	53
2016 Q3	$818K	Sell	27,539 -814	-3%	-$20.2K	0.07%	42
2016 Q2	$574K	Buy	28,353 +1,298	+5%	+$23.6K	0.05%	47
2016 Q1	$488K	Sell	27,055 -249,632	-90%	-$4.33M	0.05%	44
2015 Q4	$7.29M	Sell	276,687 -90,798	-25%	-$2.04M	0.55%	36
2015 Q3	$7.84M	Sell	367,485 -10,750	-3%	-$297K	0.59%	34
2015 Q2	$9.67M	Buy	+378,235	New	+$10.8M	0.79%	36

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Redmile Group's BPMC Position: Q3 2024 in Review

Redmile Group sold out of Blueprint Medicines (BPMC) in Q3 2024, closing a stake of 94,405 shares — an estimated $10.2M sold.

Redmile Group first reported a position in BPMC in Q2 2015 and held it in 10 quarters. The position peaked at $18.6M in Q2 2017. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

Redmile Group reported no remaining Blueprint Medicines position as of Q3 2024 after selling out during the quarter.
Redmile Group sold 94,405 Blueprint Medicines shares in Q3 2024, an estimated $10.2M.
Redmile Group first reported a position in Blueprint Medicines in Q2 2015 and held it in 10 quarters.
Redmile Group's Blueprint Medicines position peaked at $18.6M in Q2 2017.
319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on Redmile Group's 13F filing for Q3 2024, filed 14 Nov 2024.